Challenges in the application of quantitative approaches in risk assessment: A case study with di-(2-ethylhexyl)phthalate

Critical Reviews in Toxicology

Volumn 41, Issue SUPPL. 2, 2011, Pages 1-72

  Gentry, P Robinan ^a   Clewell III, Harvey J ^b   Clewell, Rebecca ^b   Campbell, Jerry ^b   Van Landingham, Cynthia ^a   Shipp, Annette M ^a  

^a ENVIRON INTERNATIONAL CORPORATION   (United States)

^b HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

Author keywords

DEHP; dose response modeling; Methods; phthalates; risk characterization

Indexed keywords

3BETA HYDROXY DELTA5 STEROID DEHYDROGENASE; AROMATASE; CHOLECYSTOKININ; CHOLESTEROL; CYTOCHROME P450 17; CYTOCHROME P450 2C11; DI (2 ETHYLHEXYL)PHTHALATE; ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; PHTHALIC ACID; RETINOID X RECEPTOR; STEROIDOGENIC FACTOR 1; TESTOSTERONE; TESTOSTERONE 17BETA DEHYDROGENASE; UNCLASSIFIED DRUG;

ACINAR CELL; APOPTOSIS; AREA UNDER THE CURVE; BODY WEIGHT; CANCER RISK; CARCINOGENIC ACTIVITY; CELL CYCLE; CELL FUNCTION; CELL GROWTH; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; DOSE RESPONSE; DOSIMETRY; DOWN REGULATION; DRUG EXPOSURE; ENZYME ACTIVITY; FETUS WEIGHT; INCIDENCE; LEYDIG CELL; LEYDIG CELL TUMOR; LIVER CELL CARCINOMA; LUTEINIZING HORMONE BLOOD LEVEL; NONHUMAN; ORGAN WEIGHT; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SPERMATOGENESIS; TESTIS WEIGHT; TESTOSTERONE BLOOD LEVEL; TESTOSTERONE SYNTHESIS;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; PHTHALIC ACIDS; RATS; RISK ASSESSMENT; TOXICOLOGY;

EID: 80052001060     PISSN: 10408444     EISSN: 15476898     Source Type: Journal    
DOI: 10.3109/10408444.2011.599366     Document Type: Review

References (207)

1. Akaike, H. 1974. A new look at the statistical model identification. IEEE Transactions on Automatic Control 19(6):716-723.
2. Akingbemi BT, Ge R, Klinefelter GR, Zirkin BR, Hardy MP. 2004. Phthalate-induced Leydig cell hyperplasia is associated with multiple endocrine disturbances. Proc Natl Acad Sci U S A 101:775-780. (Pubitemid 38121034)
3. Akingbemi BT, Youker RT, Sottas CM, Ge R, Katz E, Klinefelter GR, Zirkin BR, Hardy MP. 2001. Modulation of rat Leydig cell steroidogenic function by di(2-ethylhexyl)phthalate. Biol Reprod 65:1252-1259. (Pubitemid 32927595)
4. Albro PW. 1986. Absorption, metabolism, and excretion of di(2- ethylhexyl) phthalate by rats and mice. Environ Health Perspect 65:293-298. (Pubitemid 16117497)
5. Albro PW, Hass JR, Peck CC, Jordan ST, Corbett JT, Schroeder J. 1982. Applications of isotope differentiation for metabolic studies with di-(2-ethylhexyl) phthalate. J Environ Sci Health B 17:701-714. (Pubitemid 13051467)
6. Albro PW, Moore B. 1974. Identification of the metabolites of simple phthalate diesters in rat urine. J Chromatogr 94:209-218.
7. Alexander B. 2001. Mortality study of workers employed at the 3M Cottage Grove facility. Final Report. Division of Environmental and Occupational Health, School of Public Health, University of Minnesota.
8. Alexander BH, Olsen GW, Burris JM, Mandel JH, Mandel JS. 2003. Mortality of employees of a perfluorooctanesulphonyl fluoride manufacturing facility. Occup Environ Med 60:722-729. (Pubitemid 37203427)
9. Andersen ME, Clewell HJ, 3rd, Gargas ML, MacNaughton MG, Reitz RH, Nolan RJ, McKenna MJ. 1991. Physiologically based pharmacokinetic modeling with dichloromethane, its metabolite, carbon monoxide, and blood carboxyhemoglobin in rats and humans. Toxicol Appl Pharmacol 108:14-27.
10. Andersen ME, MacNaughton MG, Clewell HJ, 3rd, Paustenbach DJ. 1987. Adjusting exposure limits for long and short exposure periods using a physiological pharmacokinetic model. Am Ind Hyg Assoc J 48:335-343. (Pubitemid 17060040)
11. Andrade AJ, Grande SW, Talsness CE, Gericke C, Grote K, Golombiewski A, Sterner-Kock A, Chahoud I. 2006c. A dose response study following in utero and lactational exposure to di-(2-ethylhexyl) phthalate (DEHP): reproductive effects on adult male offspring rats. Toxicology 228:85-97. (Pubitemid 44550227)
12. Andrade AJ, Grande SW, Talsness CE, Grote K, Chahoud I. 2006b. A dose-response study following in utero and lactational exposure to di-(2-ethylhexyl)-phthalate (DEHP): non-monotonic dose- response and low dose effects on rat brain aromatase activity. Toxicology 227:185-192. (Pubitemid 44429936)
13. Andrade AJ, Grande SW, Talsness CE, Grote K, Golombiewski A, Sterner-Kock A, Chahoud I. 2006a. A dose-response study following in utero and lactational exposure to di-(2-ethylhexyl) phthalate (DEHP): effects on androgenic status, developmental landmarks and testicular histology in male offspring rats. Toxicology 225:64-74.
14. Ashby J, Brady A, Elcombe CR, Elliott BM, Ishmael J, Odum J, Tugwood JD, Kettle S, Purchase IF. 1994. Mechanistically-based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis. Hum Exp Toxicol 13 Suppl 2:S1-117 (Pubitemid 24356585)
15. Atanassova NN, Walker M, McKinnell C, Fisher JS, Sharpe RM. 2005. Evidence that androgens and oestrogens, as well as folliclestimulating hormone, can alter Sertoli cell number in the neonatal rat. J Endocrinol 184:107-117. (Pubitemid 40207566)
16. U.S. Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry. ATSDR Agency for Toxic Substances and Disease Registry
17. ATSDR (Agency for Toxic Substances and Disease Registry). 2002. Toxicological profile for Di(2-ethylhexyl)phthalate.
18. Barnes DG, Daston GP, Evans JS, Jarabek AM, Kavlock RJ, Kimmel CA, Park C, Spitzer HL. 1995. Benchmark Dose Workshop: criteria for use of a benchmark dose to estimate a reference dose. Regul Toxicol Pharmacol 21:296-306.
19. Barton HA. 2005. Computational pharmacokinetics during developmental windows of susceptibility. J Toxicol Environ Health A 68:889-900. (Pubitemid 43026024)
20. Barton HA, Clewell HJ, 3rd. 2000. Evaluating noncancer effects of trichloroethylene: dosimetry, mode of action, and risk assessment. Environ Health Perspect 108 Suppl 2:323-334. (Pubitemid 30420990)
21. Beall MH, van den Wijngaard JP, van Gemert MJ, Ross MG. 2007. Amniotic fluid water dynamics. Placenta 28:816-823. (Pubitemid 47074377)
22. Bentley P, Calder I, Elcombe C, Grasso P, Stringer D, Wiegand HJ. 1993. Hepatic peroxisome proliferation in rodents and its significance for humans. Food Chem Toxicol 31:857-907. (Pubitemid 24026082)
23. Biegel LB, Hurtt ME, Frame SR, O'Connor JC, Cook JC. 2001. Mechanisms of extrahepatic tumor induction by peroxisome proliferators in male CD rats. Toxicol Sci 60:44-55. (Pubitemid 32229826)
24. Biegel LB, Liu RC, Hurtt ME, Cook JC. 1995. Effects of ammonium perfluorooctanoate on Leydig cell function: in vitro, in vivo, and ex vivo studies. Toxicol Appl Pharmacol 134:18-25.
25. Boobis AR, Cohen SM, Dellarco V, McGregor D, Meek ME, Vickers C, Willcocks D, Farland W. 2006. IPCS framework for analyzing the relevance of a cancer mode of action for humans. Crit Rev Toxicol 36:781-792. (Pubitemid 44800328)
26. Boobis AR, Doe JE, Heinrich-Hirsch B, Meek ME, Munn S, Ruchirawat M, Schlatter J, Seed J, Vickers C. 2008. IPCS framework for analyzing the relevance of a noncancer mode of action for humans. Crit Rev Toxicol 38:87-96. (Pubitemid 351225507)
27. Borch J, Metzdorff SB, Vinggaard AM, Brokken L, Dalgaard M. 2006. Mechanisms underlying the anti-androgenic effects of diethylhexyl phthalate in fetal rat testis. Toxicology 223:144-155. (Pubitemid 43728621)
28. Bosland MC. 1996. Hormonal factors in carcinogenesis of the prostate and testis in humans and in animal models. Prog Clin Biol Res 394:309-352.
29. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP. 1997. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13:407-484. (Pubitemid 27314117)
30. Butenhoff J, Costa G, Elcombe C, Farrar D, Hansen K, Iwai H, Jung R, Kennedy G, Jr., Lieder P, Olsen G. 2002. Toxicity of ammonium perfluorooctanoate in male cynomolgus monkeys after oral dosing for 6 months. Toxicol Sci 69:244-257.
31. Cahill TM, Cousins I, Mackay D. 2003. Development and application of a generalized physiologically based pharmacokinetic model for multiple environmental contaminants. Environ Toxicol Chem 22:26-34. (Pubitemid 35471317)
32. Calafat AM, Brock JW, Silva MJ, Gray LE, Jr., Reidy JA, Barr DB, Needham LL. 2006. Urinary and amniotic fluid levels of phthalate monoesters in rats after the oral administration of di(2-ethylhexyl) phthalate and di-n-butyl phthalate. Toxicology 217:22-30. (Pubitemid 41758389)
33. CALEPA (California Environmental Protection Agency). 1997. Public Health Goal for Di(2-Ethylhexyl)phthalate (DEHP) in drinking water. Pesticide and Environmental Toxicology Section, Office of Environmental Health Hazard Assessment, California Environmental Proection Agency.
34. Cattley RC. 2004. Peroxisome proliferators and receptor-mediated hepatic carcinogenesis. Toxicol Pathol 32 Suppl 2:6-11. (Pubitemid 38993909)
35. Cattley RC, DeLuca J, Elcombe C, Fenner-Crisp P, Lake BG, Marsman DS, Pastoor TA, Popp JA, Robinson DE, Schwetz B,andandothers. 1998. Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans? Regul Toxicol Pharmacol 27:47-60. (Pubitemid 28289021)
36. CDC (Centers for Disease Control and Prevention). 2005. D.O.H.H.S (ed.) Third National Report on Human Exposure to Environmental Chemicals, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, 2005.
37. Chevalier S, Roberts RA. 1998. Perturbation of rodent hepatocyte growth control by nongenotoxic hepatocarcinogens: mechanisms and lack of relevance for human health (review). Oncol Rep 5:1319-1327. (Pubitemid 28474070)
38. Chu I, Villeneuve DC, Secours V, Franklin C, Rock G, Viau A. 1978. Metabolism and tissue distribution of mono-2-ethylhexyl phthalate in the rat. Drug Metab Dispos 6:146-149. (Pubitemid 8349039)
39. Clegg ED, Cook JC, Chapin RE, Foster PM, Daston GP. 1997. Leydig cell hyperplasia and adenoma formation: mechanisms and relevance to humans. Reprod Toxicol 11:107-121. (Pubitemid 27152426)
40. Clewell HJ, 3rd, Andersen ME. 1985. Risk assessment extrapolations and physiological modeling. Toxicol Ind Health 1:111-131.
41. Clewell HJ, 3rd, Andersen ME. 1989. Biologically motivated models for chemical risk assessment. Health Phys 57 Suppl 1:129-137. (Pubitemid 20092249)
42. Clewell HJ, 3rd, Gentry PR, Covington TR, Gearhart JM. 2000. Development of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment. Environ Health Perspect 108 Suppl 2:283-305. (Pubitemid 30420987)
43. Clewell HJ, Gearhart JM, Gentry PR, Covington TR, VanLandingham CB, Crump KS, Shipp AM. 1999. Evaluation of the uncertainty in an oral reference dose for methylmercury due to interindividual variability in pharmacokinetics. Risk Anal 19:547-558. (Pubitemid 29493850)
44. Clewell HJ, Gentry PR, Covington TR, Sarangapani R, Teeguarden JG. 2004. Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Toxicol Sci 79:381-393. (Pubitemid 38786895)
45. Clewell HJ, Gentry PR, Gearhart JM, Allen BC, Andersen ME. 1995. Considering pharmacokinetic and mechanistic information in cancer risk assessments for environmental contaminants: examples with vinyl chloride and trichloroethylene. Chemosphere 31:2561-2578.
46. Clewell HJ, Gentry PR, Gearhart JM, Allen BC, Andersen ME. 2001a. Comparison of cancer risk estimates for vinyl chloride using animal and human data with a PBPK model. Sci Total Environ 274:37-66. (Pubitemid 32591381)
47. Clewell RA, Clewell HJ, 3rd. 2008. Development and specification of physiologically based pharmacokinetic models for use in risk assessment. Regul Toxicol Pharmacol 50:129-143. (Pubitemid 50013231)
48. Clewell RA, Gearhart JM. 2002. Pharmacokinetics of toxic chemicals in breast milk: use of PBPK models to predict infant exposure. Environ Health Perspect 110:A333-A337 (Pubitemid 34661936)
49. Clewell RA, Kremer JJ, Williams CC, Campbell JL, Jr., Andersen ME, Borghoff SJ. 2008. Tissue exposures to free and glucuronidated monobutylyphthalate in the pregnant and fetal rat following exposure to di-n-butylphthalate: evaluation with a PBPK model. Toxicol Sci 103:241-259. (Pubitemid 351659597)
50. Clewell RA, Merrill EA, Gearhart JM, Robinson PJ, Sterner TR, Mattie DR, Clewell HJ, 3rd. 2007. Perchlorate and radioiodide kinetics across life stages in the human: using PBPK models to predict dosimetry and thyroid inhibition and sensitive subpopulations based on developmental stage. J Toxicol Environ Health A 70:408-428. (Pubitemid 46514945)
51. Clewell RA, Merrill EA, Robinson PJ. 2001b. The use of physiologically based models to integrate diverse data sets and reduce uncertainty in the prediction of perchlorate and iodide kinetics across life stages and species. Toxicol Ind Health 17:210-222. (Pubitemid 36098366)
52. Clewell RA, Merrill EA, Yu KO, Mahle DA, Sterner TR, Mattie DR, Robinson PJ, Fisher JW, Gearhart JM. 2003. Predicting fetal perchlorate dose and inhibition of iodide kinetics during gestation: a physiologically-based pharmacokinetic analysis of perchlorate and iodide kinetics in the rat. Toxicol Sci 73:235-255. (Pubitemid 36701730)
53. Cohen SM. 2004. Human carcinogenic risk evaluation: an alternative approach to the two-year rodent bioassay. Toxicol Sci 80:225-229. (Pubitemid 39136376)
54. Cohen SM, Meek ME, Klaunig JE, Patton DE, Fenner-Crisp PA. 2003. The human relevance of information on carcinogenic modes of action: overview. Crit Rev Toxicol 33:581-589. (Pubitemid 38037443)
55. Cook JC, Klinefelter GR, Hardisty JF, Sharpe RM, Foster PM. 1999. Rodent Leydig cell tumorigenesis: a review of the physiology, pathology, mechanisms, and relevance to humans. Crit Rev Toxicol 29:169-261. (Pubitemid 29169595)
56. Cook JC, Murray SM, Frame SR, Hurtt ME. 1992. Induction of Leydig cell adenomas by ammonium perfluorooctanoate: a possible endocrinerelated mechanism. Toxicol Appl Pharmacol 113:209-217.
57. Corley R. 1996. Assessing the risk of hemolysis in humans exposed to 2-butoxyethanol using a physiologically-based pharmacokinetic model. Occupational Hygiene 2:45-55.
58. Corley RA, Bormett GA, Ghanayem BI. 1994. Physiologically based pharmacokinetics of 2-butoxyethanol and its major metabolite, 2-butoxyacetic acid, in rats and humans. Toxicol Appl Pharmacol 129:61-79. (Pubitemid 24352623)
59. Corley RA, Mast TJ, Carney EW, Rogers JM, Daston GP. 2003. Evaluation of physiologically based models of pregnancy and lactation for their application in children's health risk assessments. Crit Rev Toxicol 33:137-211. (Pubitemid 36432873)
60. Corley RA, Mendrala AL, Smith FA, Staats DA, Gargas ML, Conolly RB, Andersen ME, Reitz RH. 1990. Development of a physiologically based pharmacokinetic model for chloroform. Toxicol Appl Pharmacol 103:512-527. (Pubitemid 20154730)
61. Corton JC, Lapinskas PJ. 2005. Peroxisome proliferator-activated receptors: mediators of phthalate ester-induced effects in the male reproductive tract? Toxicol Sci 83:4-17. (Pubitemid 40123326)
62. David RM. 2006. Proposed mode of action for in utero effects of some phthalate esters on the developing male reproductive tract. Toxicol Pathol 34:209-219.
63. David RM, Moore MR, Cifone MA, Finney DC, Guest D. 1999. Chronic peroxisome proliferation and hepatomegaly associated with the hepatocellular tumorigenesis of di(2-ethylhexyl)phthalate and the effects of recovery. Toxicol Sci 50:195-205. (Pubitemid 29407081)
64. David RM, Moore MR, Finney DC, Guest D. 2000a. Chronic toxicity of di(2-ethylhexyl)phthalate in rats. Toxicol Sci 55:433-443. (Pubitemid 30353252)
65. David RM, Moore MR, Finney DC, Guest D. 2000b. Chronic toxicity of di(2-ethylhexyl)phthalate in mice. Toxicol Sci 58:377-385. (Pubitemid 32042435)
66. Dedrick RL. 1973. Animal scale-up. J Pharmacokinet Biopharm 1:435-461.
67. DeLuca JG, Doebber TW, Kelly LJ, Kemp RK, Molon-Noblot S, Sahoo SP, Ventre J, Wu MS, Peters JM, Gonzalez FJ,andandothers. 2000. Evidence for peroxisome proliferator-activated receptor (PPAR)alpha-independent peroxisome proliferation: effects of PPARgamma/delta-specific agonists in PPARalpha-null mice. Mol Pharmacol 58:470-476.
68. Dostal LA, Weaver RP, Schwetz BA. 1987. Transfer of di(2-ethylhexyl) phthalate through rat milk and effects on milk composition and the mammary gland. Toxicol Appl Pharmacol 91:315-325. (Pubitemid 18050970)
69. Doull J, Cattley R, Elcombe C, Lake BG, Swenberg J, Wilkinson C, Williams G, van Gemert M. 1999. A cancer risk assessment of di(2-ethylhexyl)phthalate: application of the new U.S. EPA Risk Assessment Guidelines. Regul Toxicol Pharmacol 29:327-357. (Pubitemid 29323788)
70. el-Masri HA, Thomas RS, Benjamin SA, Yang RS. 1995. Physiologically based pharmacokinetic/pharmacodynamic modeling of chemical mixtures and possible applications in risk assessment. Toxicology 105:275-282. (Pubitemid 26038249)
71. Fennell TR, Krol WL, Sumner SC, Snyder RW. 2004. Pharmacokinetics of dibutylphthalate in pregnant rats. Toxicol Sci 82:407-418. (Pubitemid 39600067)
72. Fisher JS, Macpherson S, Marchetti N, Sharpe RM. 2003. Human testicular dysgenesis syndrome': a possible model using in-utero exposure of the rat to dibutyl phthalate. Hum Reprod 18:1383-1394. (Pubitemid 36840943)
73. Fisher JW. 2000. Physiologically based pharmacokinetic models for trichloroethylene and its oxidative metabolites. Environ Health Perspect 108 Suppl 2:265-273. (Pubitemid 30420985)
74. Fisher JW, Gargas ML, Allen BC, Andersen ME. 1991. Physiologically based pharmacokinetic modeling with trichloroethylene and its metabolite, trichloroacetic acid, in the rat and mouse. Toxicol Appl Pharmacol 109:183-195.
75. Fisher JW, Whittaker TA, Taylor DH, Clewell HJ, 3rd, Andersen ME. 1989. Physiologically based pharmacokinetic modeling of the pregnant rat: a multiroute exposure model for trichloroethylene and its metabolite, trichloroacetic acid. Toxicol Appl Pharmacol 99:395-414. (Pubitemid 19189754)
76. Foster PM. 2006. Disruption of reproductive development in male rat offspring following in utero exposure to phthalate esters. Int J Androl 29:140-147; discussion 181-185.
77. Foster PM, Mylchreest E, Gaido KW, Sar M. 2001. Effects of phthalate esters on the developing reproductive tract of male rats. Hum Reprod Update 7:231-235. (Pubitemid 32440285)
78. Fromme H, Bolte G, Koch HM, Angerer J, Boehmer S, Drexler H, Mayer R, Liebl B. 2007. Occurrence and daily variation of phthalate metabolites in the urine of an adult population. Int J Hyg Environ Health 210:21-33. (Pubitemid 46110974)
79. Gazouli M, Yao ZX, Boujrad N, Corton JC, Culty M, Papadopoulos V. 2002. Effect of peroxisome proliferators on Leydig cell peripheraltype benzodiazepine receptor gene expression, hormone-stimulated cholesterol transport, and steroidogenesis: role of the peroxisome proliferator-activator receptor alpha. Endocrinology 143:2571-2583. (Pubitemid 34701320)
80. Ge RS, Chen GR, Dong Q, Akingbemi B, Sottas CM, Santos M, Sealfon SC, Bernard DJ, Hardy MP. 2007a. Biphasic effects of postnatal exposure to diethylhexylphthalate on the timing of puberty in male rats. J Androl 28:513-520. (Pubitemid 47057032)
81. Ge RS, Chen GR, Tanrikut C, Hardy MP. 2007b. Phthalate ester toxicity in Leydig cells: developmental timing and dosage considerations. Reprod Toxicol 23:366-373. (Pubitemid 46602931)
82. Gentry P, Haber L, McDonald T, Zhao Q, Covington T, Nance P, Clewell III H, Lipscomb J, Barton H. 2004. Data for physiologically based pharmacokinetic modeling in neonatal animals: physiological parameters in mice and Sprague-Dawley rats. J Children Health 2:363-411.
83. Gentry PR, Covington TR, Clewell HJ, 3rd. 2003. Evaluation of the potential impact of pharmacokinetic differences on tissue dosimetry in offspring during pregnancy and lactation. Regul Toxicol Pharmacol 38:1-16. (Pubitemid 36873799)
84. Gerrity T, Henry C. 1990. Principles of route-to-route extrapolation for risk assessment. New York, NY: Elsevier. p. 1-12.
85. Gilliland FD, Mandel JS. 1993. Mortality among employees of a perfluorooctanoic acid production plant. J Occup Med 35:950-954. (Pubitemid 23285042)
86. Goldenthal E, Jessup D, Geil R, Mehring J. 1978. Fluorad Fluorochemical FC-143 Ninety Day Subacute Rhesus Monkey Toxicity Study. 137-090. International Research and Development Corporation.
87. Grande SW, Andrade AJ, Talsness CE, Grote K, Chahoud I. 2006. A dose-response study following in utero and lactational exposure to di(2-ethylhexyl)phthalate: effects on female rat reproductive development. Toxicol Sci 91:247-254.
88. Grande SW, Andrade AJ, Talsness CE, Grote K, Golombiewski A, Sterner-Kock A, Chahoud I. 2007. A dose-response study following in utero and lactational exposure to di-(2-ethylhexyl) phthalate (DEHP): reproductive effects on adult female offspring rats. Toxicology 229:114-122. (Pubitemid 44889269)
89. Guyton KZ, Chiu WA, Bateson TF, Jinot J, Scott CS, Brown RC, Caldwell JC. 2009. A reexamination of the PPAR-alpha activation mode of action as a basis for assessing human cancer risks of environmental contaminants. Environ Health Perspect 117:1664-1672.
90. Haber F. 1924. Zur Geschichte des Gaskrieges (1924). On the history of gas warfare. In: Funf Vortrage aus den Jahren 1920-1923 (Five Lectures from the years 1920-1923). Berlin: Springer. p 76-92.
91. Hanefeld M, Kemmer C, Kadner E. 1983. Relationship between morphological changes and lipid-lowering action of p-chlorphenoxyisobutyric acid (CPIB) on hepatic mitochondria and peroxisomes in man. Atherosclerosis 46:239-246. (Pubitemid 13191880)
92. Hanwell A, Linzell JL. 1973. The time course of cardiovascular changes in lactation in the rat. J Physiol 233:93-109.
93. Herath CB, Watanabe G, Wanzhu J, Noguchi J, Akiyama K, Kuramoto K, Groome NP, Taya K. 2001. Elevated levels of inhibin-A and immunoreactive inhibin in aged male Wistar rats with testicular Leydig cell tumor. J Androl 22:838-846. (Pubitemid 32781274)
94. Hinton RH, Mitchell FE, Mann A, Chescoe D, Price SC, Nunn A, Grasso P, Bridges JW. 1986. Effects of phthalic acid esters on the liver and thyroid. Environ Health Perspect 70:195-210. (Pubitemid 17034351)
95. Hogberg J, Hanberg A, Berglund M, Skerfving S, Remberger M, Calafat AM, Filipsson AF, Jansson B, Johansson N, Appelgren M, Hakansson H. 2008. Phthalate Diesters and Their Metabolites in Human Breast Milk, Blood or Serum, and Urine as Biomarkers of Exposure in Vulnerable Populations. Environmental Health Perspectives 116(3):334-339. (Pubitemid 351395601)
96. Howdeshell KL, Rider CV, Wilson VS, Gray LE, Jr. 2008. Mechanisms of action of phthalate esters, individually and in combination, to induce abnormal reproductive development in male laboratory rats. Environ Res 108:168-176.
97. Hunt MC, Lindquist PJ, Peters JM, Gonzalez FJ, Diczfalusy U, Alexson SE. 2000. Involvement of the peroxisome proliferator-activated receptor alpha in regulating long-chain acyl-CoA thioesterases. J Lipid Res 41:814-823. (Pubitemid 30314137)
98. IARC (International Agency for Research on Cancer). 1995. IARC Technical Report No. 24. Peroxisome Proliferation and Its Role in Carcinogenesis. World Health Organization: International Agency for Research on Cancer. Lyon, France: IARC Press.
99. ICRP (International Commission on Radiological Protection). 2002. Basic Anatomical and Physiological Data for Use in Radiological Protection: Reference Values: Ed. J. Valentin. ICRP Publication 89, Ann. ICRP 32. p. 1-277.
100. IPCS (International Programme on Chemical Safety). 2005. IPCS framework for analyzing the relevance of a cancer mode of action for humans.IPCS Workshop 1-29.
101. Ito Y, Yamanoshita O, Asaeda N, Tagawa Y, Lee CH, Aoyama T, Ichihara G, Furuhashi K, Kamijima M, Gonzalez FJ,andandothers. 2007. Di(2-ethylhexyl) phthalate induces hepatic tumorigenesis through a peroxisome proliferator-activated receptor alpha-independent pathway. J Occup Health 49:172-182. (Pubitemid 47036465)
102. Ji B, Bi Y, Simeone D, Mortensen RM, Logsdon CD. 2001. Human pancreatic acinar cells lack functional responses to cholecystokinin and gastrin. Gastroenterology 121:1380-1390. (Pubitemid 33140455)
103. Ji B, Bi Y, Simeone D, Mortensen RM, Logsdon CD. 2002. Human pancreatic acinar cells do not respond to cholecystokinin. Pharmacol Toxicol 91:327-332. (Pubitemid 36132437)
104. Johanson G, Filser JG. 1993. A physiologically based pharmacokinetic model for butadiene and its metabolite butadiene monoxide in rat and mouse and its significance for risk extrapolation. Arch Toxicol 67:151-163. (Pubitemid 23104868)
105. Kang KS, Lee YS, Kim HS, Kim SH. 2002. DI-(2-ethylhexyl) phthalateinduced cell proliferation is involved in the inhibition of gap junctional intercellular communication and blockage of apoptosis in mouse Sertoli cells. J Toxicol Environ Health A 65:447-459. (Pubitemid 34264159)
106. Kavlock R, Barr D, Boekelheide K, Breslin W, Breysse P, Chapin R, Gaido K, Hodgson E, Marcus M, Shea K,andandothers. 2006. NTP-CERHR Expert Panel Update on the Reproductive and Developmental Toxicity of di(2-ethylhexyl) phthalate. Reprod Toxicol 22:291-399.
107. Kessler W, Numtip W, Grote K, Csanady GA, Chahoud I, Filser JG. 2004. Blood burden of di(2-ethylhexyl) phthalate and its primary metabolite mono(2-ethylhexyl) phthalate in pregnant and nonpregnant rats and marmosets. Toxicol Appl Pharmacol 195:142-53. (Pubitemid 38293147)
108. Keys DA, Wallace DG, Kepler TB, Conolly RB. 1999. Quantitative evaluation of alternative mechanisms of blood and testes disposition of di(2-ethylhexyl) phthalate and mono(2-ethylhexyl) phthalate in rats. Toxicol Sci 49:172-185. (Pubitemid 29300404)
109. Keys DA, Wallace DG, Kepler TB, Conolly RB. 2000. Quantitative evaluation of alternative mechanisms of blood disposition of di(nbutyl) phthalate and mono(n-butyl) phthalate in rats. Toxicol Sci 53:173-184. (Pubitemid 30100134)
110. Klaunig JE, Babich MA, Baetcke KP, Cook JC, Corton JC, David RM, DeLuca JG, Lai DY, McKee RH, Peters JM,andandothers. 2003. PPARalpha agonist-induced rodent tumors: modes of action and human relevance. Crit Rev Toxicol 33:655-780. (Pubitemid 38037444)
111. Kleymenova E, Swanson C, Boekelheide K, Gaido KW. 2005. Exposure in utero to di(n-butyl) phthalate alters the vimentin cytoskeleton of fetal rat Sertoli cells and disrupts Sertoli cell-gonocyte contact. Biol Reprod 73:482-490. (Pubitemid 41170203)
112. Kluwe WM. 1982. Overview of phthalate ester pharmacokinetics in mammalian species. Environ Health Perspect 45:3-9. (Pubitemid 13223093)
113. Knight CH, Docherty AH, Peaker M. 1984. Milk yield in rats in relation to activity and size of the mammary secretory cell population. J Dairy Res 51:29-35.
114. Knight CH, Peaker M. 1982. Mammary cell proliferation in mice during pregnancy and lactation in relation to milk yield. Q J Exp Physiol 67:165-177. (Pubitemid 12191115)
115. Koch HM, Bolt HM, Angerer J. 2004. Di(2-ethylhexyl)phthalate (DEHP) metabolites in human urine and serum after a single oral dose of deuterium-labelled DEHP. Arch Toxicol 78:123-130. (Pubitemid 38657193)
116. Koch HM, Bolt HM, Preuss R, Angerer J. 2005. New metabolites of di(2-ethylhexyl)phthalate (DEHP) in human urine and serum after single oral doses of deuterium-labelled DEHP. Arch Toxicol 79:367-376. (Pubitemid 41040172)
117. Koch HM, Rossbach B, Drexler H, Angerer J. 2003. Internal exposure of the general population to DEHP and other phthalates- determination of secondary and primary phthalate monoester metabolites in urine. Environ Res 93:177-185. (Pubitemid 37083327)
118. Kurahashi N, Kondo T, Omura M, Umemura T, Ma M, Kishi R. 2005. The effects of subacute inhalation of di (2-ethylhexyl) phthalate (DEHP) on the testes of prepubertal Wistar rats. J Occup Health 47:437-444. (Pubitemid 41436308)
119. LaBorde JB, Hansen DK, Young JF, Sheehan DM, Holson RR. 1992. Prenatal dexamethasone exposure in rats: effects of dose, age at exposure, and drug-induced hypophagia on malformations and fetal organ weights. Fundam Appl Toxicol 19:545-554. (Pubitemid 23013125)
120. Lai DY. 2004. Rodent carcinogenicity of peroxisome proliferators and issues on human relevance. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 22:37-55. (Pubitemid 38802823)
121. Li LH, Jester WF, Jr., Laslett AL, Orth JM. 2000. A single dose of Di-(2- ethylhexyl) phthalate in neonatal rats alters gonocytes, reduces sertoli cell proliferation, and decreases cyclin D2 expression. Toxicol Appl Pharmacol 166:222-229. (Pubitemid 30640632)
122. Li Y, Hao Y, Owyang C. 1995. Evidence for autoregulation of cholecystokinin secretion during diversion of bile pancreatic juice in rats. Gastroenterology 109:231-238.
123. Liu K, Lehman KP, Sar M, Young SS, Gaido K. 2004. Gene expression profiling following in utero exposure to phthalate esters reveals new gene targets in the etiology of testicular dysgenesis. Biol Reprod 73(1):180-192. (Pubitemid 40863613)
124. Liu RC, Hahn C, Hurtt ME. 1996. The direct effect of hepatic peroxisome proliferators on rat Leydig cell function in vitro. Fundam Appl Toxicol 30:102-108.
125. Longnecker DS. 1987. Interface between adaptive and neoplastic growth in the pancreas. Gut 28 Suppl:253-258.
126. Louie DS, May D, Miller P, Owyang C. 1986. Cholecystokinin mediates feedback regulation of pancreatic enzyme secretion in rats. Am J Physiol 250:G252-259
127. Lovekamp-Swan T, Davis BJ. 2003. Mechanisms of phthalate ester toxicity in the female reproductive system. Environ Health Perspect 111:139-145. (Pubitemid 36305308)
128. Lucier GW, McDaniel OS. 1977. Steroid and non-steroid UDP glucuronyltransferase: glucuronidation of synthetic estrogens as steroids. J Steroid Biochem 8:867-872. (Pubitemid 8163946)
129. Lucier GW, Sonawane BR, McDaniel OS, Hook GE. 1975. Postnatal stimulation of hepatic microsomal enzymes following administration of TCDD to pregnant rats. Chem Biol Interact 11:15-26.
130. Luquita MG, Catania VA, Pozzi EJ, Veggi LM, Hoffman T, Pellegrino JM, Ikushiro S, Emi Y, Iyanagi T, Vore M,andandothers. 2001. Molecular basis of perinatal changes in UDP-glucuronosyltransferase activity in maternal rat liver. J Pharmacol Exp Ther 298:49-56. (Pubitemid 32574509)
131. Ma M, Kondo T, Ban S, Umemura T, Kurahashi N, Takeda M, Kishi R. 2006. Exposure of prepubertal female rats to inhaled di(2- ethylhexyl)phthalate affects the onset of puberty and postpubertal reproductive functions. Toxicol Sci 93:164-171. (Pubitemid 44288259)
132. Mann S, Droz PO, Vahter M. 1996a. A physiologically based pharmacokinetic model for arsenic exposure. II. Validation and application in humans. Toxicol Appl Pharmacol 140:471-486. (Pubitemid 26366872)
133. Mann S, Droz PO, Vahter M. 1996b. A physiologically based pharmacokinetic model for arsenic exposure. I. Development in hamsters and rabbits. Toxicol Appl Pharmacol 137:8-22. (Pubitemid 26095854)
134. Martino-Andrade AJ, Chahoud I. 2010. Reproductive toxicity of phthalate esters. Mol Nutr Food Res 54:148-157.
135. Meachem S, von Schonfeldt V, Schlatt S. 2001. Spermatogonia: stem cells with a great perspective. Reproduction 121:825-834. (Pubitemid 32547311)
136. Meek ME, Bucher JR, Cohen SM, Dellarco V, Hill RN, Lehman- McKeeman LD, Longfellow DG, Pastoor T, Seed J, Patton DE. 2003. A framework for human relevance analysis of information on carcinogenic modes of action. Crit Rev Toxicol 33:591-653. (Pubitemid 38040084)
137. Mennear J. 1988. Toxicology and Carcinogenesis Studies of Trichloroethylene in Four Strains of Rat. NTP Technical Report 273 (NIH Publication NO 88-2529).
138. Mes J, Coffin DE, Campbell DS. 1974. Di-n-butyl-and di-2-ethylhexyl phthalate in human adipose tissue. Bull Environ Contam Toxicol 12:721-725.
139. Mylchreest E, Sar M, Cattley RC, Foster PM. 1999. Disruption of androgen-regulated male reproductive development by di(nbutyl) phthalate during late gestation in rats is different from flutamide. Toxicol Appl Pharmacol 156:81-95. (Pubitemid 29196571)
140. Mylchreest E, Sar M, Wallace DG, Foster PM. 2002. Fetal testosterone insufficiency and abnormal proliferation of Leydig cells and gonocytes in rats exposed to di(n-butyl) phthalate. Reprod Toxicol 16:19-28. (Pubitemid 34303390)
141. Naessany S, Picon R. 1982. Onset of a feedback inhibition by testosterone in male rat fetuses. Biol Neonate 41:234-239. (Pubitemid 12124005)
142. Naismith DJ, Richardson DP, Pritchard AE. 1982. The utilization of protein and energy during lactation in the rat, with particular regard to the use of fat accumulated in pregnancy. Br J Nutr 48:433-441.
143. NAS (National Academy of Sciences). 1983. Risk Assessment in the Federal Government: Managing the Process. Washington, DC: National Academy Press
144. NAS (National Academy of Sciences) 2007. Toxicity Testing in the 21st century: A Vision and a Strategy. Washington, DC: The National Academy Press
145. NAS (National Academy of Sciences). 2008. Phthalates and cumulative risk assessment. Washington, DC: The National Acdemy Press.
146. NAS (National Academy of Sciences). 2009. Science and Decisions: Advancing Risk Assessment. Washington, DC: National Academy Press
147. Neale MG, Parke DV. 1973. Effects of pregnancy on the metabolism of drugs in the rat and rabbit. Biochem Pharmacol 22:1451-1461.
148. Ng KM, Chu J, Bronaugh RL, Franklin CA, Somers DA. 1992. Percutaneous absorption and metabolism of pyrene, benzo[a] pyrene, and di(2-ethylhexyl) phthalate: comparison of in vitro and in vivo results in the hairless guinea pig. Toxicology and Applied Pharmacology 115(2):216-223.
149. Noriega NC, Howdeshell KL, Furr J, Lambright CR, Wilson VS, Gray LE, Jr. 2009. Pubertal administration of DEHP delays puberty, suppresses testosterone production, and inhibits reproductive tract development in male Sprague-Dawley and Long-Evans rats. Toxicol Sci 111:163-178.
150. NTP (National Toxicology Program). 1982. Carcinogenesis bioassay of di(2-ethylhexyl)phthalate (CAS No. 117-81-7) in F344 rats and B6C3F1 mice (feed study). Research Triangle Park, NC: U.S. Department of Health and Human Services, Public Health Services, National Institute of Health. NTP publication no. 217.
151. NTP (National Toxicology Program). 2004. Diethylhexylphthalate: Multigenerational Reproductive Assessment by Continuous Breeding When Administered to Sprague-Dawley Rats in the Diet. TRC Study No7244-200, NTP-RACB-98-004.
152. O'Flaherty E. 1989. Interspecies conversion of kinetically equivalent doses. Risk Analysis 9:587-598.
153. O'Flaherty EJ. 1995. Physiologically based models for bone-seeking elements. V. Lead absorption and disposition in childhood. Toxicol Appl Pharmacol 131:297-308.
154. O'Flaherty EJ, Scott W, Schreiner C, Beliles RP. 1992. A physiologically based kinetic model of rat and mouse gestation: disposition of a weak acid. Toxicol Appl Pharmacol 112:245-256.
155. Obourn JD, Frame SR, Bell RH, Jr., Longnecker DS, Elliott GS, Cook JC. 1997a. Mechanisms for the pancreatic oncogenic effects of the peroxisome proliferator Wyeth-14,643. Toxicol Appl Pharmacol 145:425-436. (Pubitemid 27346533)
156. Obourn JD, Frame SR, Chiu T, Solomon TE, Cook JC. 1997b. Evidence that A8947 enhances pancreas growth via a trypsin inhibitor mechanism. Toxicol Appl Pharmacol 146:116-126. (Pubitemid 27406403)
157. Olsen GW, Burris JM, Burlew MM, Mandel JH. 2000. Plasma cholecystokinin and hepatic enzymes, cholesterol and lipoproteins in ammonium perfluorooctanoate production workers. Drug Chem Toxicol 23:603-620.
158. Olsen GW, Gilliland FD, Burlew MM, Burris JM, Mandel JS, Mandel JH. 1998. An epidemiologic investigation of reproductive hormones in men with occupational exposure to perfluorooctanoic acid. J Occup Environ Med 40:614-622. (Pubitemid 28334614)
159. Overturf ML, Druilhet RE, Liehr JG, Kirkendall WM, Caprioli RM. 1979. Phthalate esters in normal and pathological human kidneys. Bull Environ Contam Toxicol 22:536-542. (Pubitemid 9246089)
160. Park HW, Shepard TH. 1994. Volume and glucose concentration of rat amniotic fluid: effects on embryo nutrition and axis rotation. Teratology 49:465-469. (Pubitemid 24190529)
161. Parks LG, Ostby JS, Lambright CR, Abbott BD, Klinefelter GR, Barlow NJ, Gray LE, Jr. 2000. The plasticizer diethylhexyl phthalate induces malformations by decreasing fetal testosterone synthesis during sexual differentiation in the male rat. Toxicol Sci 58:339-349. (Pubitemid 32042432)
162. Payan JP, Marty JP, Fabry JP, Beydon D, Boudry I, Ferrari E, Canel F, Grandclaude MC, Vincent CM. 2001. In vivo and in vitro percutaneous absorption of [(14)C]di-N-butylphthalate in rat. Drug Metab Dispos 29:843-854. (Pubitemid 32488641)
163. Payne AH, Jaffe RB. 1972. Comparison of androgen synthesis in human fetal testis and adrenal: 3 -hydroxysteroid dehydrogenaseisomerase and 17 -steroid dehydrognase activities. Biochim Biophys Acta 279:202-207.
164. Pollack GM, Li RC, Ermer JC, Shen DD. 1985. Effects of route of administration and repetitive dosing on the disposition kinetics of di(2-ethylhexyl) phthalate and its mono-de-esterified metabolite in rats. Toxicol Appl Pharmacol 79:246-256. (Pubitemid 15013729)
165. Post SM, Duez H, Gervois PP, Staels B, Kuipers F, Princen HM. 2001. Fibrates suppress bile acid synthesis via peroxisome proliferatoractivated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression. Arterioscler Thromb Vasc Biol 21:1840-1845. (Pubitemid 34219790)
166. Rakusan K, Marcinek H. 1973. Postnatal development of the cardiac output distribution in rat. Biol Neonate 22:58-63.
167. Rao MS, Subbarao V. 1995. Incidence of pancreatic and testicular tumors in rats treated with ciprofibrate, a peroxisome proliferator. Cancer Lett 97:185-188.
168. Reitz RH, Mendrala AL, Corley RA, Quast JF, Gargas ML, Andersen ME, Staats DA, Conolly RB. 1990. Estimating the risk of liver cancer associated with human exposures to chloroform using physiologically based pharmacokinetic modeling. Toxicol Appl Pharmacol 105:443-459. (Pubitemid 20373275)
169. Rider CV, Wilson VS, Howdeshell KL, Hotchkiss AK, Furr JR, Lambright CR, Gray LE, Jr. 2009. Cumulative effects of in utero administration of mixtures of "antiandrogens" on male rat reproductive development. Toxicol Pathol 37:100-113.
170. Rodricks JV, Swenberg JA, Borzelleca JF, Maronpot RR, Shipp AM. 2010. Triclosan: a critical review of the experimental data and development of margins of safety for consumer products. Crit Rev Toxicol 40:422-484.
171. Rowland IR, Cottrell RC, Phillips JC. 1977. Hydrolysis of phthalate esters by the gastro-intestinal contents of the rat. Food Cosmet Toxicol 15:17-21. (Pubitemid 8058063)
172. Rusyn I, Peters JM, Cunningham ML. 2006. Modes of action and species-specific effects of di-(2-ethylhexyl)phthalate in the liver. Crit Rev Toxicol 36:459-479. (Pubitemid 43904319)
173. Rusyn I, Rose ML, Bojes HK, Thurman RG. 2000. Novel role of oxidants in the molecular mechanism of action of peroxisome proliferators. Antioxid Redox Signal 2:607-621.
174. Sarangapani R, Gentry PR, Covington TR, Teeguarden JG, Clewell HJ, 3rd. 2003. Evaluation of the potential impact of age- and genderspecific lung morphology and ventilation rate on the dosimetry of vapors. Inhal Toxicol 15:987-1016. (Pubitemid 37158651)
175. Seed J, Carney EW, Corley RA, Crofton KM, DeSesso JM, Foster PM, Kavlock R, Kimmel G, Klaunig J, Meek ME,andandothers. 2005. Overview: Using mode of action and life stage information to evaluate the human relevance of animal toxicity data. Crit Rev Toxicol 35:664-672.
176. Seo KW, Kim KB, Kim YJ, Choi JY, Lee KT, Choi KS. 2004. Comparison of oxidative stress and changes of xenobiotic metabolizing enzymes induced by phthalates in rats. Food Chem Toxicol 42:107-114. (Pubitemid 37421330)
177. Shaban Z, Soliman M, El-Shazly S, El-Bohi K, Abdelazeez A, Kehelo K, Kim HS, Muzandu K, Ishizuka M, Kazusaka A,andandothers. 2005. AhR and PPARalpha: antagonistic effects on CYP2B and CYP3A, and additive inhibitory effects on CYP2C11. Xenobiotica 35:51-68. (Pubitemid 40459217)
178. Short RD, Robinson EC, Lington AW, Chin AE. 1987. Metabolic and peroxisome proliferation studies with di(2-ethylhexyl)phthalate in rats and monkeys. Toxicol Ind Health 3:185-195.
179. Sibinski L. 1988. Two-Year Oral (Diet) Toxicity/Carcinogenicity Study of Fluorochemical FC-143 in Rats (Riker Experiment No. 0281CR0012). 0281CR0012. Riker Laboratories, Inc. St. Paul, MN.
180. Sjoberg P, Bondesson U, Hammarlund M. 1985. Non-linearities in the pharmacokinetics of di-(2-ethylhexyl) phthalate and metabolites in male rats. Arch Toxicol 58:72-77. (Pubitemid 16183336)
181. Stolc V, Knopp J, Stolcova E. 1966. Iodine, solid diet, water and milk intake by lactating rats and their offsprings. Physiol Bohemoslov 15:219-225.
182. Swan SH, Main KM, Liu F, Stewart SL, Kruse RL, Calafat AM, Mao CS, Redmon JB, Ternand CL, Sullivan S,andandothers. 2005. Decrease in anogenital distance among male infants with prenatal phthalate exposure. Environ Health Perspect 113:1056-1061. (Pubitemid 41149638)
183. Tan YM, Liao KH, Clewell HJ, 3rd. 2007. Reverse dosimetry: interpreting trihalomethanes biomonitoring data using physiologically based pharmacokinetic modeling. J Expo Sci Environ Epidemiol 17:591-603. (Pubitemid 350126884)
184. Tan YM, Liao KH, Conolly RB, Blount BC, Mason AM, Clewell HJ. 2006. Use of a physiologically based pharmacokinetic model to identify exposures consistent with human biomonitoring data for chloroform. J Toxicol Environ Health A 69:1727-1756.
185. Tanaka A, Matsumoto A, Yamaha T. 1978. Biochemical studies on phthalic esters. III. Metabolism of dibutyl phthalate (DBP) in animals. Toxicology 9:109-123. (Pubitemid 8307323)
186. Tangoku A, Doi R, Chowdhury P, Blevins GT, Jr., Pasley JN, Rayford PL. 1993. Exogenous administration of estradiol and cholecystokinin alters exocrine pancreatic function in rats. Int J Pancreatol 13:81-86. (Pubitemid 23118447)
187. Teirlynck OA, Belpaire F. 1985. Disposition of orally administered di-(2-ethylhexyl) phthalate and mono-(2-ethylhexyl) phthalate in the rat. Arch Toxicol 57:226-230. (Pubitemid 16253421)
188. Thomford P. 2000. 4-Week Capsule Toxicity Study with Ammonium Perfluorooctanoate (APFO) in Cynomolgus Monkeys (Draft Report). 6329-230. Covance Laboratories, Inc. Madison, WI.
189. Tucker M, Orton T. 1995. Comparative toxicology of hypolipidemic fibrates. Britol, PA: Taylor and Francis. p.
190. Turek FW, Desjardins C. 1979. Development of Leydig cell tumors and onset of changes in the reproductive and endocrine systems of aging F344 rats. J Natl Cancer Inst 63:969-975. (Pubitemid 10247890)
191. Ubel FA, Sorenson SD, Roach DE. 1980. Health status of plant workers exposed to fluorochemicals-a preliminary report. Am Ind Hyg Assoc J 41:584-589. (Pubitemid 10034524)
192. USEPA (United States Environmental Protection Agency). 1986. Guidelines for Carcinogen Risk Assessment. Risk Assessment Forum. Washington, DC: U.S. Environmental Protection Agency. EPA/630/R-00/004.
193. USEPA (United States Environmental Protection Agency). 1992. Draft report: a cross-species scaling factor for carcinogen risk assessment based on equivalence of mg/kg3/4/day. Federal Register 57(109):24152-24173.
194. USEPA (United States Environmental Protection Agency). Guidelines for Carcinogen Risk Assessment. Review Draft. NCEA-F-0644. U.S. Environmental Protection Agency. Washington, D.C.
195. USEPA 1999. Guidelines for Carcinogen Risk Assessment. Risk Assessment Forum, Review Draft, July 1999, NCEA-F- 0644.
196. USEPA United States Environmental Protection Agency). 2000a. Benchmark Dose Technical Guidance Document (External Review Draft). U.S. Environmental Protection Agency. Washington, DC. EPA/630/R-00/001.
197. USEPA (United States Environmental Protection Agency). 2000b. Science Policy Handbook. Risk Characterization. Office of Research and Development, U.S. Environmental Protection Agency, Washington, DC.EPA 100-B-00-002.
198. USEPA (United States Environmental Protection Agency). 2002. Child-Specific Exposure Factors Handbook. EPA Publication: EPA-600-P-00-002B.
199. USEPA (United States Environmental Protection Agency). 2003. Proposed OPPTS Science Policy: PPARalpha-Mediated Hepatocarcinogenesis in Rodents and Relevance to Human health risk Assessments. U.S. Environmental Protection Agency, P. T. S. Office of Prevention.
200. SEPA (United States Environmental Protection Agency). 2005. Guidelines for Carcinogen Risk Assessment Risk Assessment Forum. Washington, DC: U.S. Environmental Protection Agency. EPA/630/P-03/001b.
201. Voss C, Zerban H, Bannasch P, Berger MR. 2005. Lifelong exposure to di-(2-ethylhexyl)-phthalate induces tumors in liver and testes of Sprague-Dawley rats. Toxicology 206:359-71. (Pubitemid 39601021)
202. Walrath J. 1996. Final DuPont epidemiology surveillance report: Mortality and cancer incidence surveillance at Washington Works.
203. Ward JM, Peters JM, Perella CM, Gonzalez FJ. 1998. Receptor and nonreceptor-mediated organ-specific toxicity of di(2-ethylhexyl) phthalate (DEHP) in peroxisome proliferator-activated receptor alpha-null mice. Toxicol Pathol 26:240-6. (Pubitemid 28155330)
204. Wishart GJ. 1978. Functional heterogeneity of UDPglucuronosyltransferase as indicated by its differential development and inducibility by glucocorticoids. Demonstration of two groups within the enzyme's activity towards twelve substrates. Biochem J 174:485-489. (Pubitemid 8403655)
205. Wittassek M, Wiesmuller GA, Koch HM, Eckard R, Dobler L, Muller J, Angerer J, Schluter C. 2007. Internal phthalate exposure over the last two decades-a retrospective human biomonitoring study. Int J Hyg Environ Health 210:319-333. (Pubitemid 46618121)
206. Woodyatt NJ, Lambe KG, Myers KA, Tugwood JD, Roberts RA. 1999. The peroxisome proliferator (PP) response element upstream of the human acyl CoA oxidase gene is inactive among a sample human population: significance for species differences in response to PPs. Carcinogenesis 20:369-72. (Pubitemid 29112621)
207. Wykoff MH. 1971. Weight changes of the developing rat conceptus. Am J Vet Res 32:1633-1635.